Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study

被引:15
|
作者
Fava, Maurizio [1 ]
Menard, Francois [2 ]
Davidsen, Charlotte Kampp [2 ]
Baker, Ross A. [3 ]
机构
[1] Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA
[2] H Lundbeck & Co AS, Valby, Denmark
[3] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
关键词
PHYSICAL FUNCTIONING QUESTIONNAIRE; ANGER ATTACKS; INADEQUATE RESPONSE; VALIDITY; SCALE; MICE; ANTIDEPRESSANTS; RELIABILITY; VALIDATION; SEVERITY;
D O I
10.4088/JCP.15m10470
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD). Methods: Patients diagnosed with MDD according to DSM-IV-TR criteria who had inadequate response to antidepressant treatment continued treatment with their current antidepressant for 2 weeks. Patients still having inadequate response, and with irritability, received 6 weeks of open-label treatment with their current antidepressant at the same dose and adjunctive brexpiprazole (target dose: 3 mg/d). Brexpiprazole was discontinued at week 6, and the patients continued with their antidepressant until week 10. Changes from baseline to week 6 and week 6 to week 10 were analyzed. Results: This study was conducted between October 7, 2013, and July 30, 2014. Fifty-four patients were treated with adjunctive brexpiprazole. At week 6, clinically relevant improvements were observed in Sheehan Irritability Scale total (-21.1) and item 1 (irritable mood) (-3.5) scores, Kellner Symptom Questionnaire total (-24.4) and anger-hostility subscale (-7.7) scores, and 30-item Inventory of Depressive Symptomatology, clinician version (IDS-C30), item 6 (irritable mood) score (-1.2). More (15 patients) stopped than developed (5 patients) anger attacks during treatment, as measured by the Anger Attacks Questionnaire. The Clinical Global Impressions-Severity of Illness score improved (-1.4), as did the depressive symptoms (IDS-C30 total score, -17.8; Kellner Symptom Questionnaire depression subscale score, -7.7; and Montgomery-Asberg Depression Rating Scale total score, -14.2). Irritability symptoms worsened after brexpiprazole discontinuation, assessed at week 10. Adjunctive brexpiprazole was well tolerated. Conclusions: Adjunctive treatment with brexpiprazole may represent a strategy for patients with MDD and inadequate response to antidepressant treatment who have symptoms of irritability. (C) Copyright 2016 Physicians Postgraduate Press, Inc.
引用
收藏
页码:1695 / +
页数:9
相关论文
共 50 条
  • [21] ECONOMIC EVALUATION OF BREXPIPRAZOLE AS ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE MEXICAN NATIONAL HEALTH SYSTEM
    Soto Molina, H.
    Escobar Juarez, Y.
    Frias Gasga, A. E.
    Romero Tapia, C. G.
    Diaz Alvarez, O.
    Campos Ramirez, O.
    Marcos-Olivan, N.
    VALUE IN HEALTH, 2022, 25 (07) : S421 - S421
  • [22] Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment
    Weisler, Richard H.
    Ota, Ai
    Tsuneyoshi, Kana
    Perry, Pamela
    Weiller, Emmanuelle
    Baker, Ross A.
    Sheehan, David V.
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 204 : 40 - 47
  • [23] Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy
    Krystal, Andrew D.
    Mittoux, Aurelia
    Lindsten, Annika
    Baker, Ross A.
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 278 : 288 - 295
  • [24] Aripiprazole as adjunctive therapy in patients with major depressive disorder
    Graber, Mark A.
    Dachs, Robert
    Darby-Stewart, Andrea
    AMERICAN FAMILY PHYSICIAN, 2008, 78 (03) : 308 - +
  • [25] Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
    Thase, Michael E.
    Weiller, Emmanuelle
    Zhang, Peter
    Weiss, Catherine
    McIntyre, Roger S.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 37 - 45
  • [26] Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study
    Therrien, Francois
    Ward, Caroline
    Chokka, Pratap
    Habert, Jeffrey
    Ismail, Zahinoor
    Mcintyre, Roger S.
    Mackenzie, Erin M.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2024, 69 (07): : 513 - 523
  • [27] A Randomized, Double-Blind, Placebo-Controlled Study of Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
    Hobart, Mary
    Skuban, Aleksandar
    Zhang, Peter
    Yang, Ye
    Augustine, Carol
    Brewer, Claudette
    Hefting, Nanco
    Sanchez, Raymond
    McQuade, Robert
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S533 - S533
  • [28] Brexpiprazole for treatment-resistant major depressive disorder
    Fornaro, Michele
    Fusco, Andrea
    Anastasia, Annalisa
    Cattaneo, Carlo Ignazio
    De Berardis, Domenico
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (16) : 1925 - 1933
  • [29] Content validity of the Sheehan Irritability Scale in patients with major depressive disorder
    Mannix, Sally
    Hassan, Mariam
    Tummala, Raj
    Locklear, Julie C.
    Revicki, Dennis A.
    Khan, Sajjad
    Dunbar, Geoffrey C.
    Eriksson, Hans
    Sheehan, David V.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (02) : 110 - 117
  • [30] Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis
    Yoon, Seoyoung
    Shin, Cheolmin
    Jeon, Sangwon
    Han, Changsu
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 103 - 103